{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:33:04Z","timestamp":1793057584839,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lund University","id":[{"id":"https:\/\/ror.org\/012a77v79","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Antimicrobial resistance increases with the use of broad-spectrum antibiotics. Studies evaluating antibiotic stewardship are in high demand. Is piperacillin\/tazobactam non-inferior to carbapenems regarding 30-day mortality among patients with bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacterales?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, multicenter, non-inferiority, cohort study assessed adult patients with bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacterales in southern Sweden from 2013 to 2022. Patients were categorized according to the first therapy they received two consecutive doses of (piperacillin\/tazobactam or a carbapenem). The primary outcome was 30-day all-cause mortality, measured from when the positive blood cultures were taken. The absolute risk difference for this outcome was calculated for all patients, and two propensity score matched cohorts (empirical and effective), with two different delta limits (5% and 2%). Secondary outcomes included intensive care unit admission, early clinical response, superinfections, relapsed infection and one-year mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 644 patients were included. In the piperacillin\/tazobactam group, 26\/309 patients met the primary outcome, compared to 27\/335 patients in the carbapenem group. The absolute risk difference (-0.4%) was statistically significant in the propensity score matched empirical cohort [1-sided 97.5% confidence interval]: -\u221e to 4.0,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008). Piperacillin\/tazobactam was non-inferior to carbapenems for all the secondary outcomes in the same cohort, except for the early clinical response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings indicate that piperacillin\/tazobactam is non-inferior to carbapenems for treating extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections, with an acceptable 5% increase in 30-day mortality. We suggest that piperacillin\/tazobactam should be used more frequently to decrease antimicrobial resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-025-02496-x","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T10:01:20Z","timestamp":1744797680000},"page":"1769-1777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Piperacillin\/tazobactam versus carbapenems for 30-day mortality in patients with ESBL-producing Enterobacterales bloodstream infections: a retrospective, multicenter, non-inferiority, cohort study"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4696-4588","authenticated-orcid":false,"given":"Thomas","family":"Sahlstr\u00f6m M\u00e5nsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Askemyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torgny","family":"Sunnerhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Riesbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Mellhammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"issue":"1","key":"2496_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","volume":"19","author":"A Cassini","year":"2019","unstructured":"Cassini A, Hogberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European economic area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56\u201366.","journal-title":"Lancet Infect Dis"},{"key":"2496_CR2","unstructured":"Antimicrobial resistance surveillance in. Europe 2022\u20132020 data. Available at: www.ecdc.europa.eu\/sites\/default\/files\/documents\/Joint-WHO-ECDC-AMR-report-2022.pdf. Accessed 2023-05-15."},{"key":"2496_CR3","volume-title":"Europe 2023\u2013\u20092021 data","author":"Antimicrobial resistance surveillance in","year":"2023","unstructured":"Antimicrobial resistance surveillance in. Europe 2023\u2013\u20092021 data. Stockholm: European Centre for Disease Prevention and Control and World Health Organization; 2023."},{"issue":"10","key":"2496_CR4","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1128\/AAC.00607-13","volume":"57","author":"M McLaughlin","year":"2013","unstructured":"McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH. Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae. Antimicrob Agents Chemother. 2013;57(10):5131\u20133.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2496_CR5","first-page":"CD003543","volume":"2","author":"P Davey","year":"2017","unstructured":"Davey P, Marwick CA, Scott CL, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017;2(2):CD003543.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2496_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1473-3099(14)70950-8","volume":"15","author":"PN Harris","year":"2015","unstructured":"Harris PN, Tambyah PA, Paterson DL. beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis. 2015;15(4):475\u201385.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2496_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.diagmicrobio.2003.11.007","volume":"49","author":"DS Burgess","year":"2004","unstructured":"Burgess DS, Hall RG 2. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis. 2004;49(1):41\u20136.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"10","key":"2496_CR8","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jama.2018.12163","volume":"320","author":"PNA Harris","year":"2018","unstructured":"Harris PNA, Tambyah PA, Lye DC, et al. Effect of Piperacillin-Tazobactam vs meropenem on 30-Day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: A randomized clinical trial. JAMA. 2018;320(10):984\u201394.","journal-title":"JAMA"},{"key":"2496_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jgar.2024.08.002","volume":"39","author":"M Gatti","year":"2024","unstructured":"Gatti M, Cojutti PG, Pea F. Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing enterobacterales bloodstream infections: A systematic review and meta-analysis. J Glob Antimicrob Resist. 2024;39:27\u201336.","journal-title":"J Glob Antimicrob Resist"},{"key":"2496_CR10","unstructured":"Sweden OSo. Population in the country, counties and municipalities on 31 December 2023 and Population Change in 2023. Available at: https:\/\/www.scb.se\/en\/finding-statistics\/statistics-by-subject-area\/population\/population-composition\/population-statistics\/pong\/tables-and-graphs\/population-statistics---year\/population-in-the-country-counties-and-municipalities-on-31-december-2023-and-population-change-in-2023\/. Accessed 2024-09-26."},{"issue":"9","key":"2496_CR11","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1097\/CCM.0000000000001142","volume":"43","author":"SA Sterling","year":"2015","unstructured":"Sterling SA, Miller WR, Pryor J, Puskarich MA, Jones AE. The impact of timing of antibiotics on outcomes in severe Sepsis and septic shock: A systematic review and Meta-Analysis. Crit Care Med. 2015;43(9):1907\u201315.","journal-title":"Crit Care Med"},{"issue":"18","key":"2496_CR12","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jama.279.18.1452","volume":"279","author":"EA Halm","year":"1998","unstructured":"Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998;279(18):1452\u20137.","journal-title":"JAMA"},{"issue":"5","key":"2496_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1503\/cmaj.050051","volume":"173","author":"K Rockwood","year":"2005","unstructured":"Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489\u201395.","journal-title":"CMAJ"},{"issue":"6","key":"2496_CR14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"9","key":"2496_CR15","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/cid\/ciz528","volume":"70","author":"H Henderson","year":"2020","unstructured":"Henderson H, Luterbach CL, Cober E, et al. The Pitt bacteremia score predicts mortality in nonbacteremic infections. Clin Infect Dis. 2020;70(9):1826\u201333.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2496_CR16","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for Sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"key":"2496_CR17","unstructured":"Monegro AF, Muppidi V, Regunath H. Hospital-Acquired infections. StatPearls. Treasure Island (FL). 2024."},{"issue":"1","key":"2496_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1128\/JCM.36.1.105-109.1998","volume":"36","author":"F Blot","year":"1998","unstructured":"Blot F, Schmidt E, Nitenberg G, et al. Earlier positivity of central-venous- versus peripheral-blood cultures is highly predictive of catheter-related sepsis. J Clin Microbiol. 1998;36(1):105\u20139.","journal-title":"J Clin Microbiol"},{"issue":"5","key":"2496_CR19","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1086\/432472","volume":"41","author":"R Khatib","year":"2005","unstructured":"Khatib R, Riederer K, Saeed S, et al. Time to positivity in Staphylococcus aureus bacteremia: possible correlation with the source and outcome of infection. Clin Infect Dis. 2005;41(5):594\u20138.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2496_CR20","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis campaign: international guidelines for management of Sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063\u2013143.","journal-title":"Crit Care Med"},{"issue":"1","key":"2496_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkn444","volume":"63","author":"CG Giske","year":"2009","unstructured":"Giske CG, Sundsfjord AS, Kahlmeter G, et al. Redefining extended-spectrum beta-lactamases: balancing science and clinical need. J Antimicrob Chemother. 2009;63(1):1\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2496_CR22","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1128\/AAC.00365-16","volume":"60","author":"B Gutierrez-Gutierrez","year":"2016","unstructured":"Gutierrez-Gutierrez B, Perez-Galera S, Salamanca E, et al. A multinational, preregistered cohort study of beta-Lactam\/beta-Lactamase inhibitor combinations for treatment of bloodstream infections due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016;60(7):4159\u201369.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2496_CR23","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","volume":"163","author":"MA Brookhart","year":"2006","unstructured":"Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149\u201356.","journal-title":"Am J Epidemiol"},{"issue":"9","key":"2496_CR24","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/aje\/kwq224","volume":"172","author":"PC Austin","year":"2010","unstructured":"Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol. 2010;172(9):1092\u20137.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2496_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150\u201361.","journal-title":"Pharm Stat"},{"issue":"3","key":"2496_CR26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/jssam\/smy019","volume":"7","author":"C Franco","year":"2019","unstructured":"Franco C, Little RJA, Louis TA, Slud EV. Comparative study of confidence intervals for proportions in complex sample surveys. J Surv Stat Methodol. 2019;7(3):334\u201364.","journal-title":"J Surv Stat Methodol"},{"issue":"5","key":"2496_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4097\/kjae.2013.64.5.402","volume":"64","author":"H Kang","year":"2013","unstructured":"Kang H. The prevention and handling of the missing data. Korean J Anesthesiol. 2013;64(5):402\u20136.","journal-title":"Korean J Anesthesiol"},{"key":"2496_CR28","volume-title":"R: A Language and environment for statistical computing","author":"R Development Core Team","year":"2024","unstructured":"R Development Core Team. R: A Language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2024."},{"issue":"10","key":"2496_CR29","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1093\/jac\/dkz226","volume":"74","author":"JR Lenhard","year":"2019","unstructured":"Lenhard JR, Bulman ZP. Inoculum effect of beta-lactam antibiotics. J Antimicrob Chemother. 2019;74(10):2825\u201343.","journal-title":"J Antimicrob Chemother"},{"key":"2496_CR30","doi-asserted-by":"crossref","unstructured":"Kowalska-Krochmal B, Dudek-Wicher R. The minimum inhibitory concentration of antibiotics: methods, interpretation, clinical relevance. Pathogens 2021;10(2).","DOI":"10.3390\/pathogens10020165"},{"key":"2496_CR31","doi-asserted-by":"crossref","unstructured":"Husna A, Rahman MM, Badruzzaman ATM et al. Extended-Spectrum beta-Lactamases (ESBL): challenges and opportunities. Biomedicines 2023;11(11).","DOI":"10.3390\/biomedicines11112937"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02496-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02496-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02496-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:01:57Z","timestamp":1793055717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02496-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2496"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02496-x","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Swedish ethical review authority (Project-ID 2023-02388-01).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}